{"id":124,"date":"2018-01-17T05:16:00","date_gmt":"2018-01-17T00:16:00","guid":{"rendered":"http:\/\/www.policymed.com\/nevada-posts-faq-and-reporting-requirements-on-transparency-law\/"},"modified":"2018-05-04T00:29:11","modified_gmt":"2018-05-03T19:29:11","slug":"nevada-posts-faq-and-reporting-requirements-on-transparency-law","status":"publish","type":"post","link":"https:\/\/www.policymed.com\/2018\/01\/nevada-posts-faq-and-reporting-requirements-on-transparency-law.html","title":{"rendered":"Nevada Posts FAQ and Reporting Requirements on Transparency Law"},"content":{"rendered":"<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\">As we <a href=\"http:\/\/www.policymed.com\/2018\/01\/nevada-proposes-drug-transparency-regulations.html\">posted last week<\/a>, the Nevada draft regulations are up and starting to become a hot topic. The same day as our last post, Nevada updated the <a href=\"http:\/\/dhhs.nv.gov\/uploadedFiles\/dhhsnvgov\/content\/HCPWD\/FAQ%20-%20Drug%20Transparency%20-%20Revised%20011018.pdf?n=9221\">Frequently Asked Questions<\/a> and the <a href=\"http:\/\/dhhs.nv.gov\/uploadedFiles\/dhhsnvgov\/content\/HCPWD\/SB%20539%20Reporting%20Updated%20010918.pdf\">SB 539 Reporting requirements<\/a>. \u00a0<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\"><strong>Frequently Asked Questions<\/strong><\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\">The <a href=\"http:\/\/dhhs.nv.gov\/uploadedFiles\/dhhsnvgov\/content\/HCPWD\/FAQ%20-%20Drug%20Transparency%20-%20Revised%20011018.pdf?n=9221\">two-page FAQ document<\/a> provides some helpful answers to common questions, such as whether the reporting for pharmaceutical representatives is the responsibility of the individual or of the manufacturer. Nevada notes that it is the responsibility of both and then lists specific requirements. For example, manufacturers are required to submit a list of names of all pharmaceutical representatives who market prescription drugs in Nevada while each pharmaceutical representative is required to submit a report of all compensation or prescription drug that was provided to a provider of health care that is licensed, certified, or registered in this State, among others.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\">The FAQ also confirms that the law applies equally to all pharmaceutical representatives and not just those who are engaging in the sales and marketing of the diabetes-related treatments state on the website.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\">The FAQ also includes links to report formatting and other specifics for prescription drug manufacturers and pharmacy benefit managers.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\"><strong>Reporting Requirements<\/strong><\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\"><u>Drug Manufacturers<\/u><\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\">As required under the law, prescription manufacturers must <a href=\"http:\/\/dhhs.nv.gov\/uploadedFiles\/dhhsnvgov\/content\/HCPWD\/SB%20539%20Reporting%20Updated%20010918.pdf\">submit a report<\/a> to the Nevada Department of Health and Human Services (DHHS) with the below information, for prescription drugs posted on the DHHS website. This report must be submitted via email annually by April 1<sup>st<\/sup> of each year for the previous calendar year. DHHS then compiles a report and posts it in accordance with NRS 439.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\"> <a class=\"asset-img-link\" style=\"display: inline;\" href=\"http:\/\/policymed.typepad.com\/.a\/6a00e5520572bb883401b8d2cf7902970c-pi\"><img decoding=\"async\" class=\"asset asset-image at-xid-6a00e5520572bb883401b8d2cf7902970c image-full img-responsive\" title=\"Manufacturer requirements\" src=\"http:\/\/policymed.typepad.com\/.a\/6a00e5520572bb883401b8d2cf7902970c-800wi\" alt=\"Manufacturer requirements\" border=\"0\" \/><\/a><br \/>\n<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\"><u>Pharmacy Benefit Managers<\/u><\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\">PBMs are also required to submit a report to DHHS by April 1<sup>st<\/sup> of each year. The required information for that report is as follows.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\"> <a class=\"asset-img-link\" style=\"display: inline;\" href=\"http:\/\/policymed.typepad.com\/.a\/6a00e5520572bb883401b8d2cf790a970c-pi\"><img decoding=\"async\" class=\"asset asset-image at-xid-6a00e5520572bb883401b8d2cf790a970c image-full img-responsive\" title=\"PBM\" src=\"http:\/\/policymed.typepad.com\/.a\/6a00e5520572bb883401b8d2cf790a970c-800wi\" alt=\"PBM\" border=\"0\" \/><\/a><br \/>\n<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\"><u>Pharmaceutical Sales Representatives<\/u><\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\">Pharmaceutical sales reps that are on a list submitted to DHHS by drug manufacturers anytime during the previous calendar year must submit their report by March 1<sup>st<\/sup> of the year, including the below items.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 12pt;\"> <a class=\"asset-img-link\" style=\"display: inline;\" href=\"http:\/\/policymed.typepad.com\/.a\/6a00e5520572bb883401b7c9452ba6970b-pi\"><img decoding=\"async\" class=\"asset asset-image at-xid-6a00e5520572bb883401b7c9452ba6970b image-full img-responsive\" title=\"Pharma Rep\" src=\"http:\/\/policymed.typepad.com\/.a\/6a00e5520572bb883401b7c9452ba6970b-800wi\" alt=\"Pharma Rep\" border=\"0\" \/><\/a><br \/>\n<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>As we posted last week, the Nevada draft regulations are up and starting to become a hot topic. The same day as our last post, Nevada updated the Frequently Asked Questions and the SB 539 Reporting requirements. \u00a0 Frequently Asked Questions The two-page FAQ document provides some helpful answers to common questions, such as whether [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3553,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24,6],"tags":[1101],"class_list":["post-124","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-state-policy","category-transparency","tag-new"],"_links":{"self":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/comments?post=124"}],"version-history":[{"count":1,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/124\/revisions"}],"predecessor-version":[{"id":3554,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/124\/revisions\/3554"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/media\/3553"}],"wp:attachment":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/media?parent=124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/categories?post=124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/tags?post=124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}